215 related articles for article (PubMed ID: 19940012)
1. A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
Sharma S; Abhyankar V; Burgess RE; Infante J; Trowbridge RC; Tarazi J; Kim S; Tortorici M; Chen Y; Robles RL
Ann Oncol; 2010 Feb; 21(2):297-304. PubMed ID: 19940012
[TBL] [Abstract][Full Text] [Related]
2. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
3. Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.
Infante JR; Reid TR; Cohn AL; Edenfield WJ; Cescon TP; Hamm JT; Malik IA; Rado TA; McGee PJ; Richards DA; Tarazi J; Rosbrook B; Kim S; Cartwright TH
Cancer; 2013 Jul; 119(14):2555-63. PubMed ID: 23605883
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
[TBL] [Abstract][Full Text] [Related]
5. Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours.
Hoh CK; Burris HA; Bendell JC; Tarazi J; Rosbrook B; Kim S; Infante JR; Reid TR
Br J Cancer; 2014 Feb; 110(4):875-81. PubMed ID: 24423921
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer.
Meyerhardt JA; Stuart K; Fuchs CS; Zhu AX; Earle CC; Bhargava P; Blaszkowsky L; Enzinger P; Mayer RJ; Battu S; Lawrence C; Ryan DP
Ann Oncol; 2007 Jul; 18(7):1185-9. PubMed ID: 17483115
[TBL] [Abstract][Full Text] [Related]
7. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
Wainberg ZA; Messersmith WA; Peddi PF; Kapp AV; Ashkenazi A; Royer-Joo S; Portera CC; Kozloff MF
Clin Colorectal Cancer; 2013 Dec; 12(4):248-54. PubMed ID: 24075777
[TBL] [Abstract][Full Text] [Related]
8. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A
Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
[TBL] [Abstract][Full Text] [Related]
10. Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy.
Miura K; Nakano H; Sakurai J; Kobayashi S; Koizumi S; Arai T; Shimamura T; Makizumi R; Yamada K; Miyajima N; Otsubo T; Koike J
Int J Clin Oncol; 2011 Jun; 16(3):257-63. PubMed ID: 21243394
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.
Messersmith WA; Jimeno A; Jacene H; Zhao M; Kulesza P; Laheru DA; Kahn Y; Spira A; Dancey J; Iacobuzio-Donahue C; Donehower RC; Carducci M; Rudek MA; Hidalgo M
Clin Colorectal Cancer; 2010 Dec; 9(5):297-304. PubMed ID: 21208844
[TBL] [Abstract][Full Text] [Related]
12. Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer.
Tebbutt N; Kotasek D; Burris HA; Schwartzberg LS; Hurwitz H; Stephenson J; Warner DJ; Chen L; Hsu CP; Goldstein D
Cancer Chemother Pharmacol; 2015 May; 75(5):993-1004. PubMed ID: 25772756
[TBL] [Abstract][Full Text] [Related]
13. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study.
Nakayama N; Sato A; Tanaka S; Shimada K; Konishi K; Sasaki E; Hibi K; Ichikawa H; Kikuchi Y; Sakuyama T; Sekikawa T; Hayashi K; Nishina H;
Invest New Drugs; 2015 Aug; 33(4):954-62. PubMed ID: 25937430
[TBL] [Abstract][Full Text] [Related]
15. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
Bokemeyer C; Bondarenko I; Makhson A; Hartmann JT; Aparicio J; de Braud F; Donea S; Ludwig H; Schuch G; Stroh C; Loos AH; Zubel A; Koralewski P
J Clin Oncol; 2009 Feb; 27(5):663-71. PubMed ID: 19114683
[TBL] [Abstract][Full Text] [Related]
16. 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study.
Bir A; Tan W; Wilding GE; Lombardo J; Fakih MG
Oncology; 2007; 72(1-2):4-9. PubMed ID: 17971679
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066
[TBL] [Abstract][Full Text] [Related]
18. A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.
Bendell JC; Hochster H; Hart LL; Firdaus I; Mace JR; McFarlane JJ; Kozloff M; Catenacci D; Hsu JJ; Hack SP; Shames DS; Phan SC; Koeppen H; Cohn AL
Oncologist; 2017 Mar; 22(3):264-271. PubMed ID: 28209746
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
Strickler JH; McCall S; Nixon AB; Brady JC; Pang H; Rushing C; Cohn A; Starodub A; Arrowood C; Haley S; Meadows KL; Morse MA; Uronis HE; Blobe GC; Hsu SD; Zafar SY; Hurwitz HI
Invest New Drugs; 2014 Apr; 32(2):330-9. PubMed ID: 24173967
[TBL] [Abstract][Full Text] [Related]
20. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Van Cutsem E; Grothey A; Prausová J; Garcia-Alfonso P; Yamazaki K; Clingan PR; Lonardi S; Kim TW; Simms L; Chang SC; Nasroulah F;
Lancet Oncol; 2015 May; 16(5):499-508. PubMed ID: 25877855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
